RanBP3 enhances nuclear export of active β-catenin independently of CRM1

被引:69
|
作者
Hendriksen, J
Fagotto, F
van der Velde, H
van Schie, M
Noordermeer, J
Fornerod, M [1 ]
机构
[1] Netherlands Canc Inst, Dept Tumor Biol, NL-1066 CX Amsterdam, Netherlands
[2] McGill Univ, Dept Biol, Montreal, PQ H3A 2T5, Canada
[3] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands
来源
JOURNAL OF CELL BIOLOGY | 2005年 / 171卷 / 05期
关键词
D O I
10.1083/jcb.200502141
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
beta-Catenin is the nuclear effector of the Wnt signaling cascade. The mechanism by which nuclear activity of beta-catenin is regulated is not well defined. Therefore, we used the nuclear marker RanGTP to screen for novel nuclear beta-catenin binding proteins. We identified a cofactor of chromosome region maintenance 1 (CRM1)-mediated nuclear export, Ran binding protein 3 (RanBP3), as a novel beta-catenin-interacting protein that binds directly to beta-catenin in a RanGTP-stimulated manner. RanBP3 inhibits beta-catenin-mediated transcriptional activation in both Wnt1- and beta-catenin-stimulated human cells. In Xenopus laevis embryos, RanBP3 interferes with beta-catenin-induced dorsoventral axis formation. Furthermore, RanBP3 depletion stimulates the Wnt pathway in both human cells and Drosophila melanogaster embryos. In human cells, this is accompanied by an increase of dephosphorylated beta-catenin in the nucleus. Conversely, overexpression of RanBP3 leads to a shift of active beta-catenin toward the cytoplasm. Modulation of beta-catenin activity and localization by RanBP3 is independent of adenomatous polyposis coli protein and CRM1. We conclude that RanBP3 is a direct export enhancer for beta-catenin, independent of its role as a CRM1-associated nuclear export cofactor.
引用
收藏
页码:785 / 797
页数:13
相关论文
共 50 条
  • [1] RanBP3 influences interactions between CRM1 and its nuclear protein export substrates
    Englmeier, L
    Fornerod, M
    Bischoff, FR
    Petosa, C
    Mattaj, IW
    Kutay, U
    EMBO REPORTS, 2001, 2 (10) : 926 - 932
  • [2] An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1
    Koyama, Masako
    Matsuura, Yoshiyuki
    EMBO JOURNAL, 2010, 29 (12): : 2002 - 2013
  • [3] Insights into the Function of the CRM1 Cofactor RanBP3 from the Structure of Its Ran-Binding Domain
    Langer, Karla
    Dian, Cyril
    Rybin, Vladimir
    Mueller, Christoph W.
    Petosa, Carlo
    PLOS ONE, 2011, 6 (02):
  • [4] A role for RanBP1 in the release of CRM1 from the nuclear pore complex in a terminal step of nuclear export
    Kehlenbach, RH
    Dickmanns, A
    Kehlenbach, A
    Guan, TL
    Gerace, L
    JOURNAL OF CELL BIOLOGY, 1999, 145 (04): : 645 - 657
  • [5] RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export
    Pathria, Gaurav
    Garg, Bhavuk
    Wagner, Christine
    Garg, Kanika
    Gschaider, Melanie
    Jalili, Ahmad
    Wagner, Stephan N.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (01) : 264 - 274
  • [6] Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals
    Fung, Ho Yee Joyce
    Fu, Szu-Chin
    Chook, Yuh Min
    ELIFE, 2017, 6
  • [7] CRM1 Promotes Capsid Disassembly and Nuclear Envelope Translocation of Adenovirus Independently of Its Export Function
    Lagadec, Floriane
    Carlon-Andres, Irene
    Ragues, Jessica
    Port, Sarah
    Wodrich, Harald
    Kehlenbach, Ralph H.
    JOURNAL OF VIROLOGY, 2022, 96 (03)
  • [8] Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358
    Engelsma, D
    Bernad, R
    Calafat, J
    Fornerod, M
    EMBO JOURNAL, 2004, 23 (18): : 3643 - 3652
  • [9] CRM1 is an export receptor for leucine-rich nuclear export signals
    Fornerod, M
    Ohno, M
    Yoshida, M
    Mattaj, IW
    CELL, 1997, 90 (06) : 1051 - 1060
  • [10] Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
    Lu, Chuanwen
    Figueroa, Jose A.
    Liu, Zhongwei
    Konala, Venu
    Aulakh, Amardeep
    Verma, Rashmi
    Cobos, Everardo
    Chiriva-Internati, Maurizio
    Gao, Weimin
    CURRENT CANCER DRUG TARGETS, 2015, 15 (07) : 575 - 592